TAS0313

**TAS0313** is a novel cancer peptide vaccine cocktail under clinical development for the treatment of solid tumors, including glioblastoma and urothelial carcinoma. It comprises three long peptides (TAS0314, TAS0315, TAS0316), collectively presenting 12 cytotoxic T lymphocyte (CTL) epitope peptides restricted by multiple HLA types (A2, A24, A3-supertypes). These peptides are derived from eight cancer-associated antigens frequently expressed in tumors: squamous cell carcinoma antigen recognized by T-cells 2 (SART2), SART3, multidrug resistance-associated protein 3 (MRP3), epidermal growth factor receptor (EGFR), Wolf-Hirschhorn syndrome candidate 2 protein (WHSC2), transmembrane protein 189 (TMEM189), tyrosine-protein kinase LCK, and parathyroid hormone-related protein (PTHRP). By stimulating both cellular (CTLs) and humoral (IgG) immune responses, TAS0313 is intended to enhance antitumor immunity. Clinical trials have confirmed its safety, tolerability, and immunogenicity in patients with advanced solid tumors. Trials evaluating its efficacy both as monotherapy and combined with pembrolizumab are ongoing[1][2][3][4][5][7][8].